Approvals to Access: A Schematic of Psychedelic Medicalization

FDA approval of novel psychedelic treatments involves a complex multi-stage pipeline spanning regulatory review, drug rescheduling, and practical healthcare integration. Following potential FDA drug approval, federal rescheduling by the DEA typically takes up to 90 days, followed by state-level rescheduling decisions that can add several months of administrative delay. Operational implementation requires Risk Evaluation and Mitigation Strategies (REMS), clinician training, facility readiness, and clear reimbursement pathways through public payers and private insurance.